Bain & Company has recently entered into a strategic partnership with Boston-based life sciences consulting firm Trinity Life Sciences, with Bain acquiring a minority stake in the company.
Trinity was founded in 1996 and employs more than 1,600 people across offices in the U.S., Canada, Germany, the U.K., and India. The firm is a leading advisor in life sciences commercialization, providing large global biopharma and medtech clients services in corporate strategy, product planning and forecasting, portfolio strategy, business development support, market intelligence and benchmarking, and proprietary technology products in data and analytics. Trinity was named to the 2022 Inc. 5000 Fastest-Growing Private Companies List, the second year in a row it has been included on the prestigious list, which represents a one-of-a-kind look at some of the most successful companies in the highly dynamic independent business segment.
“The life sciences industry is fast growing and quickly evolving, requiring both breadth of experience and depth of expertise from its advisors,” said Tim van Biesen, the head of Bain’s global healthcare practice. “This partnership delivers best-in-class capabilities to serve our clients’ comprehensive needs. By focusing on all relevant levels of life sciences organizations, we deliver the most tailored support and curated solutions to the questions and details that matter to each.”
In November 2021, Trinity recapitalized with Mount Kisco, NY-based private equity firm Kohlberg & Company, which specializes in leveraged buyouts. As part of the transaction, a new 10-person board was created at Trinity. A month prior to the recapitalization, Trinity acquired New York-based boutique life sciences strategy consulting firm CBPartners, bringing more than 75 additional consulting professionals into its fold.
David Fitzhenry, Chief Executive Officer of Trinity, commented that the partnership felt like a perfect match as the company continues to expand and deepen its client offerings, adding that the new endeavor combines both firms’ industry-leading life sciences experts, advanced data and analytics services, and Bain’s extensive capabilities in private equity, mergers & acquisitions, digital transformation, and commercial excellence.
